Oric(US:ORIC) Globenewswire·2025-12-03 21:01Core Insights - ORIC Pharmaceuticals announced two late-breaking oral presentations at the ESMO Asia Congress 2025, focusing on enozertinib (ORIC-114) data from a Phase 1b trial targeting therapeutic resistance in NSCLC [1][2][3] Presentation Details - The mini-oral presentation will cover data on previously treated patients with EGFR atypical mutant NSCLC, scheduled for December 5, 2025, at 11:38 a.m. SGT [2] - The proffered paper oral presentation will focus on previously treated and treatment-naïve patients with EGFR exon 20 mutant NSCLC, scheduled for December 6, 2025, at 10:02 a.m. SGT [3] Company Overview - ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to overcoming resistance in cancer, with a focus on developing enozertinib (ORIC-114) and ORIC-944 for various cancers [5]